Dhuwit awis saben lembar saham Addex (ADXN)

The prospects for Addex Therapeutics (ADXN) depend on the results of drug trials for dystonia and Parkinson's disease. A stable staff of biochemists in European laboratories ensures the quality of development, while a focus on partner R&D programs accelerates commercialization. Cash per share for the issuer demonstrates current liquidity, with the metric valued at 0.90, which helps assess the real value of the capital.
Rincian metrik komprehensif lan analitis Addex Therapeutics Ltd. (ADXN)

Supply chain disruption risks and pharmaceutical patent disputes require Addex Therapeutics (ADXN) to maintain a high liquidity reserve. This parameter correlates the volume of net cash with the number of shares, determining the intrinsic value of the security. The metric serves as an indicator of financial stability and protection against bankruptcy during periods of uncertainty. An excess of funds may signal stagnation in business development. The trend of highly liquid assets per share clearly demonstrates the current solvency of Addex Therapeutics (ADXN).